ArticleEndocrinology, diabetes & metabolism2026
Advanced Hybrid Closed Loop Systems in Pregnancy: A Retrospective Study of Women With Type 1 Diabetes.
Article in Endocrinology, diabetes & metabolism, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Advanced Hybrid Closed Loop Systems in Pregnancy: A Retrospective Study of Women With Type 1 Diabetes.Endocrinology, diabetes & metabolism · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundHybrid closed loop systems (HCLS) lead to improved glycaemic outcomes without the increased burden of hypoglycemia. CamAPS and Mendtronic 780G are the only systems licensed for use in pregnancy in Europe; however, all the commercially available algorithms are currently used in clinical practice. The aim of this study is to share our experience of using HCLS during pregnancy.
methodsThis is a retrospective study. We reviewed records at two teaching hospitals from January 2018-March 2023 and identified 42 women of whom 42.8% (n = 18) were established on HCLS prior to pregnancy and 57.2% (n = 24) started during pregnancy at a median of 12 weeks of gestation.
resultsTime in pregnancy target range (TIRp) (3.5-7.8 mmol/L) increased from 57% (44.5%-65%) (median, IQR) at first visit to 73% (65%-82%) (p < 0.001) at 34 weeks of gestation with 66% achieving ≥ 70% at 34 weeks. Time below range (TBR) glucose did not change significantly. There was no significant difference in TIRp at 8 or 34 weeks between those started on HCLS before versus during pregnancy. TBR at first visit was lower in those established on HCLS pre-pregnancy versus those started in pregnancy (p: 0.04) with no difference between groups at 34 weeks. There were no admissions for diabetic ketoacidosis (DKA) or severe hypoglycemia. Eleven infants (26.8%) had birthweight over 90th percentile and neonatal hypoglycemia was recorded in 9 cases (22%).
conclusionsIn our cohort, HCLS in pregnancy was effective, with 66% achieving ≥ 70% TIRp, and appears to be safe with low TBR and no episodes of DKA.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.